Results 31 to 40 of about 204,978 (241)

Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model

Frontiers in Immunology
ObjectivesThe present study aimed to assess the therapeutic efficacy of neutralizing monoclonal antibodies targeting a prominent proinflammatory cytokine in a PBMC transfer-induced humanized mouse model of systemic inflammation.MethodsInflammatory ...
Liang Zhang, Liang Zhang, Jacqueline Wax, Jacqueline Wax, Torsten Goldmann, Torsten Goldmann, Afsaneh Mehrpouyan, Afsaneh Mehrpouyan, Antje Müller, Frank Petersen, Frank Petersen, Gabriela Riemekasten, Xinhua Yu, Xinhua Yu   +13 more
doaj   +1 more source

SATISFY‐JP, a phase II multicenter open‐label study on Satralizumab, an anti‐IL‐6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune‐responsive‐phenotype: Study protocol

Pulmonary Circulation, 2023
Pulmonary arterial hypertension (PAH), an intractable disease with a poor prognosis, is commonly treated using pulmonary vasodilators modulating the endothelin, cGMP, and prostacyclin pathway.
Yuichi Tamura, Rika Takeyasu, Tomohiro Takata, Naoki Miyazaki, Ryo Takemura, Michihiko Wada, Yudai Tamura, Kohtaro Abe, Ayako Shigeta, Yu Taniguchi, Shiro Adachi, Takumi Inami, Ichizo Tsujino, Nobuhiro Tahara, Masataka Kuwana   +14 more
doaj   +1 more source

Classic and Activating Chimeric Antigen Receptors PD-1 as an Element of Multi-Target Approach to the Treatment of Hematological and Solid Neoplasms

Клиническая онкогематология, 2023
Aim. To generate anti-PD-L1 CAR-T effectors carrying extracellular domain PD-1 as antigen-recognizing site and to study their cytolytic activity as well as to functionally assess the anti-PD-L1 CAR-T effectors in vitro with a view to apply them in multi ...
Kseniya Aleksandrovna Levchuk, A. A. Goldaev, E. A. Stolyarova, P. A. Mateikovich, A. Kh. Valiullina, E. R. Bulatov, A. V. Petukhov, A. A. Daks, N. A. Barlev, E. V. Baidyuk, Ya. G. Toropova   +10 more
doaj   +1 more source

Biologics in Asthma: A Molecular Perspective to Precision Medicine

Frontiers in Pharmacology, 2022
Recent developments in therapeutic strategies have provided alternatives to corticosteroids as the cornerstone treatment for managing airway inflammation in asthma.
Brittany Salter, Brittany Salter, Paige Lacy, Manali Mukherjee, Manali Mukherjee   +4 more
doaj   +1 more source

Galectin-3 binding protein stimulated IL-6 expression is impeded by antibody intervention in SARS-CoV-2 susceptible cell lines

Scientific Reports, 2022
COVID-19 is the global pandemic that affected our population in the past 2 years. Considerable research has been done to better understand the pathophysiology of this disease and to identify new therapeutic targets, especially for severe cases.
Ana Mendes-Frias, Valentina Gallo, Valentina Iacobelli, Roberta Gentile, Giovanni Antonini, Ricardo Silvestre, Stefano Iacobelli   +6 more
doaj   +1 more source

Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody

Current pediatrics, 2018
Background. Infections are the main cause of death for patients with autoimmune rheumatic diseases. In adult patients with rheumatoid arthritis (RA), mortality caused by respiratory infections is 2–5 times higher than in the population. One of the frequent infectious complications in the course of treatment with tocilizumab, the first-choice drug for ...
Daria D. Vankova, Ekaterina I. Alekseeva, Margarita А. Soloshenko, Tatiana М. Dvoriakovskaia, Ksenia B. Isaeva, Rina V. Denisova, Anna V. Mamutova, Mariya G. Rudnitskaya, Nikolay A. Mayansky, Natal’ya Е. Tkachenko   +9 more
openaire   +3 more sources

Classical Complement Pathway Inhibition in a Pediatric Patient With Refractory Immune Thrombocytopenia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric refractory immune thrombocytopenia (rITP) is generally characterized by persistent thrombocytopenia and failure to achieve a sustained response to multiple standard therapies. We report a 4‐year‐old female with congenital tufting enteropathy, post‐intestinal transplant patient on immunosuppressants, who developed severe rITP ...
Sarah Hsieh, Susmita Sarangi, Caileigh Pudela, Catherine M. Broome, Tara K. Suntum   +4 more
wiley   +1 more source

Changes in Iron Metabolism Induced by Anti-Interleukin-6 Receptor Monoclonal Antibody are Associated with an Increased Risk of Infection

Pharmaceuticals, 2019
(1) Background: Treatment of patients with rheumatoid arthritis (RA) with an anti-IL-6 receptor (anti-IL-6R) monoclonal antibody (tocilizumab) has been found to influence iron metabolism.
Renata Ribeiro, Frederico Batista, Filipe Seguro Paula, José Delgado Alves   +3 more
doaj   +1 more source

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma

Frontiers in Immunology, 2021
Anti-CD19 chimeric antigen receptor T (CAR-T) cells have demonstrated activity against relapsed/refractory lymphomas. Cytokine release syndrome (CRS) and immune effector cell – associated neurotoxicity syndrome (ICANS) are well-known complications ...
Paolo F. Caimi, Gabriela Pacheco Sanchez, Ashish Sharma, Folashade Otegbeye, Nausheen Ahmed, Patricio Rojas, Seema Patel, Sarah Kleinsorge Block, Jennifer Schiavone, Kayla Zamborsky, Kirsten Boughan, Antoinette Hillian, Jane Reese-Koc, Mikhail Maschan, Boro Dropulic, Rafick-Pierre Sekaly, Marcos de Lima   +16 more
doaj   +1 more source

An isoform of 14‐3‐3 protein regulates transbilayer lipid movement at the plasma membrane

FEBS Letters, EarlyView.
Loss of 14‐3‐3ζ in CHO cells confers resistance to exogenous phosphatidylserine (PS) and impairs endocytosis‐independent inward flip‐flop of fluorescent PS at the plasma membrane. RNAi‐mediated knockdown reproduces this defect, while no additive effect is seen in ATP11C‐deficient cells.
Akiko Yamaji‐Hasegawa, Akira Hattori, Masafumi Tsujimoto, Toshihide Kobayashi   +3 more
wiley   +1 more source